Institute of Oncology Policlinico of Monza

Monza, Italy

Institute of Oncology Policlinico of Monza

Monza, Italy
SEARCH FILTERS
Time filter
Source Type

Bajetta E.,Institute of Oncology Policlinico of Monza | Catena L.,Institute of Oncology Policlinico of Monza | Valente M.,Institute of Oncology Policlinico of Monza | Bianco N.,Institute of Oncology Policlinico of Monza | And 2 more authors.
Anticancer Research | Year: 2012

The treatment of neuroendocrine tumours (NETs) is mainly based on their biological characteristics of aggressiveness and functional features. Radical surgery is the sole effective approach. In other types of well-differentiated tumours, hormonal therapy is the treatment of choice, as well as chemotherapy is the treatment of choice for aggressive diseases. Recent advances in the field of targeted therapies have expanded options for NETs, particularly of pancreatic neuroendocrine tumours. The radiotherapy option in NETs is based on radiopharmaceuticals targeting receptors over-expressed by these diseases and acting on the cell metabolism.


PubMed | Institute of Oncology Policlinico of Monza
Type: Journal Article | Journal: Anticancer research | Year: 2012

The treatment of neuroendocrine tumours (NETs) is mainly based on their biological characteristics of aggressiveness and functional features. Radical surgery is the sole effective approach. In other types of well-differentiated tumours, hormonal therapy is the treatment of choice, as well as chemotherapy is the treatment of choice for aggressive diseases. Recent advances in the field of targeted therapies have expanded options for NETs, particularly of pancreatic neuroendocrine tumours. The radiotherapy option in NETs is based on radiopharmaceuticals targeting receptors over-expressed by these diseases and acting on the cell metabolism.

Loading Institute of Oncology Policlinico of Monza collaborators
Loading Institute of Oncology Policlinico of Monza collaborators